TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors

Inclusion Criteria: * Confirmed diagnosis of HCC by histology/ cytology or clinical criteria * Sign informed consent * When screening for age, the age should be ≥ 18 years old * Eligible for TACE treatment * ECOG physical condition score is 0 or 1 * No prior systemic therapy for HCC, especially immunotherapy * According to the following mRECIST criteria, at least one measurable intrahepatic lesion is suitable for repeated evaluation Exclusion Criteria: * Have any history of kidney disease or nephrotic syndrome * Evidence of extrahepatic spread (EHS) * Cardiovascular diseases with clinical significance (such as activity), including unstable angina, ≥ grade 2 congestive heart failure, and arrhythmia with poor drug treatment control * Any condition representing a contraindication to TACE as determined by the investigators * Known genetic factors for bleeding or thrombosis; Any previous or current evidence indicating a tendency for bleeding * Individuals who have received immunotherapy (anti PD-1, anti PD-L1, or anti CTLA-4 treatment) * Previously received HAIC (hepatic artery infusion chemotherapy), TACE (hepatic artery chemoembolization), TAE (hepatic artery embolization), or TARE (hepatic artery radiation embolization) * Previously received systemic anti-cancer treatment for HCC ,ICC or liver metastasis.